Unexpectedly, the stratified analysis indicated that the survival rates were similar for MBC and FBC patients in the hormone receptor (HoR)-negative/HER2-positive group, whereas in the other groups, OS was better for FBC patients than MBC patients (p < 0.01). This evidence concerns the gene ERBB2 and complete blood cell count.